Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

LANTHEUS HOLDINGS, INC.

(LNTH)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/21/2021 09/22/2021 09/23/2021 09/24/2021 09/27/2021 Date
25.97(c) 26.28(c) 27.01(c) 26.97(c) 27.44 Last
277 380 186 263 966 272 261 012 427 213 Volume
+0.62% +1.19% +2.78% -0.15% +1.74% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 397 M - -
Net income 2021 -18,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -81,7x
Yield 2021 -
Sales 2022 478 M - -
Net income 2022 41,3 M - -
Net Debt 2022 - - -
P/E ratio 2022 43,5x
Yield 2022 -
Capitalization 1 855 M 1 855 M -
Capi. / Sales 2021 4,68x
Capi. / Sales 2022 3,88x
Nbr of Employees 595
Free-Float 97,2%
More Financials
Company
Lantheus Holdings, Inc. is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging. It operates in two segments: U.S. Segment and International... 
More about the company
Ratings of Lantheus Holdings, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about LANTHEUS HOLDINGS, INC.
09/13LANTHEUS : Announces Addition of PSMA PET Imaging Agent to the National Comprehensive Canc..
AQ
09/13Lantheus Announces Addition of PSMA Pet Imaging Agent to the National Comprehensive Can..
CI
09/13LANTHEUS : and RefleXion Announce Development and Commercialization Collaboration with the..
AQ
09/13Lantheus Holdings, Inc and Reflexion Medical Inc. Announce Development and Commercializ..
CI
09/10Lantheus Announces Presentation at the 2021 American Urological Association (AUA) Annua..
GL
09/02Lantheus Holdings to Present at Upcoming Investor Conferences
GL
08/12INSIDER TRENDS : Insider Extends 90-Day Selling Trend at Lantheus Holdings
MT
07/30LANTHEUS : Subsidiary's Prostate Cancer Imaging Software Gets FDA's 510(k) Clearance
MT
07/29LANTHEUS : Announces the First and Only FDA Cleared AI-Enabled PSMA Digital Application, a..
BU
07/29LANTHEUS : SVB Leerink Adjusts Lantheus Holdings' Price Target to $34 from $31, Keeps Outp..
MT
07/28LANTHEUS : Q2 Adjusted Earnings Rise, Revenue Higher; Company Raises Full-Year Guidance
MT
07/28LANTHEUS : Reports Second Quarter 2021 Financial Results (Form 8-K)
PU
07/28LANTHEUS : Management's Discussion and Analysis of Financial Condition and Results of Oper..
AQ
07/28Lantheus Holdings, Inc. Reports Earnings Results for the Second Quarter Ended June 30, ..
CI
07/28LANTHEUS HOLDINGS, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
More news
News in other languages on LANTHEUS HOLDINGS, INC.
2017Wall Street alourdie par l'énergie en attendant la Fed
More news
Analyst Recommendations on LANTHEUS HOLDINGS, INC.
More recommendations
Chart LANTHEUS HOLDINGS, INC.
Duration : Period :
Lantheus Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LANTHEUS HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 26,97 $
Average target price 32,00 $
Spread / Average Target 18,7%
EPS Revisions
Managers and Directors
Mary Anne Heino President, Chief Executive Officer & Director
Robert J. Marshall Chief Financial Officer & Treasurer
Brian A. Markison Non-Executive Chairman
Simon Robinson Senior VP-Research & Pharmaceutical Development
Istvan Molnar Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
LANTHEUS HOLDINGS, INC.99.93%1 823
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.53.23%20 232
10X GENOMICS, INC.8.87%17 094
BIOMÉRIEUX-6.98%14 875
DIASORIN S.P.A.15.14%12 549
NATERA, INC.18.69%11 078